Literature DB >> 12642378

Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.

Lucien Gazi1, Sarah A Nickolls, Philip G Strange.   

Abstract

(1) The human dopamine D(2long) (D(2L)) receptor was expressed with four different G proteins in Sf9 cells using the baculovirus expression system. When co-expressed with G(i)/G(o) G proteins (G(i1)alpha, G(i2)alpha, G(i3)alpha, or G(o)alpha, plus Gbeta(1) and Ggamma(2)), the receptor displayed a high-affinity binding site for the agonists (dopamine and NPA), which was sensitive to GTP (100 micro M), demonstrating interaction between the receptor and the different G proteins. (2) The receptor to G protein ratio (R : G ratio) was evaluated using [(3)H]-spiperone saturation binding (R) and [(35)S]-GTPgammaS saturation binding (G). R : G ratios of 1 : 12, 1 : 3, 1 : 14 and 1 : 5 were found for G(i1), G(i2), G(i3), and G(o) preparations, respectively. However, when R : G ratios of 1 : 2 and 1 : 12 were compared for G(i2) and G(o), no difference was found for the stimulation of [(35)S]-GTPgammaS binding. (3) Several agonists were tested for their ability to stimulate [(35)S]-GTPgammaS binding to membranes co-expressing the receptor and various G proteins. All the compounds tested showed agonist activity in preparations expressing G(i3) and G(o). However, for G(i2) and G(i1) preparations, compounds such as S-(-)-3-PPP and p-tyramine were unable to stimulate [(35)S]-GTPgammaS binding. (4) Most of the compounds showed higher relative efficacies (compared to dopamine) and higher potencies in the preparation expressing G(o). Comparison of the effects of different agonists in the different preparations showed that each agonist differentially activates the four G proteins. (5) We conclude that the degree of selectivity of G protein activation by the D(2L) receptor can depend on the conformation of the receptor stabilised by an agonist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642378      PMCID: PMC1573727          DOI: 10.1038/sj.bjp.0705116

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Influence of G protein type on agonist efficacy.

Authors:  Q Yang; S M Lanier
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

2.  Human 5-hydroxytryptamine(5A) receptors activate coexpressed G(i) and G(o) proteins in Spodoptera frugiperda 9 cells.

Authors:  B J Francken; K Josson; P Lijnen; M Jurzak; W H Luyten; J E Leysen
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

3.  Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype.

Authors:  Y Cordeaux; S A Nickolls; L A Flood; S G Graber; P G Strange
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

Review 4.  The ligand paradox between affinity and efficacy: can you be there and not make a difference?

Authors:  Terry Kenakin; Ongun Onaran
Journal:  Trends Pharmacol Sci       Date:  2002-06       Impact factor: 14.819

5.  Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.

Authors:  P J Pauwels; S Tardif; T Wurch; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

6.  Quantitation of the guanine nucleotide binding regulatory protein Gs in S49 cell membranes using antipeptide antibodies to alpha s.

Authors:  L A Ransnäs; P A Insel
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.157

7.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

8.  Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.

Authors:  A Newman-Tancredi; V Audinot; C Moreira; L Verrièle; M J Millan
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

9.  Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins.

Authors:  K Wenzel-Seifert; R Seifert
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

10.  Use of [3H]spiperone for labelling dopaminergic and serotonergic receptors in bovine caudate nucleus.

Authors:  R M Withy; R J Mayer; P G Strange
Journal:  J Neurochem       Date:  1981-11       Impact factor: 5.372

View more
  29 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Dopamine D3 autoreceptor inhibition enhances cocaine potency at the dopamine transporter.

Authors:  Molly M McGinnis; Cody A Siciliano; Sara R Jones
Journal:  J Neurochem       Date:  2016-08-15       Impact factor: 5.372

3.  Mechanisms of inverse agonist action at D2 dopamine receptors.

Authors:  David J Roberts; Philip G Strange
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

4.  Regional Heterogeneity of D2-Receptor Signaling in the Dorsal Striatum and Nucleus Accumbens.

Authors:  Pamela F Marcott; Sheng Gong; Prashant Donthamsetti; Steven G Grinnell; Melissa N Nelson; Amy H Newman; Lutz Birnbaumer; Kirill A Martemyanov; Jonathan A Javitch; Christopher P Ford
Journal:  Neuron       Date:  2018-04-12       Impact factor: 17.173

5.  A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions.

Authors:  Céline Laschet; Nadine Dupuis; Julien Hanson
Journal:  J Biol Chem       Date:  2018-12-28       Impact factor: 5.157

Review 6.  Understanding functional residues of the cannabinoid CB1.

Authors:  Joong-Youn Shim
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

7.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

8.  Noradrenaline stimulates cell proliferation by suppressing potassium channels via G(i/o) -protein-coupled α(1B) -adrenoceptors in human osteoblasts.

Authors:  D Kodama; A Togari
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  The brain gene expression profile of dopamine D2/D3 receptors and associated signaling proteins following amphetamine self-administration.

Authors:  H Sun; E S Calipari; T J R Beveridge; S R Jones; R Chen
Journal:  Neuroscience       Date:  2015-08-28       Impact factor: 3.590

10.  Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells.

Authors:  Douglas J Sheffler; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2008-07-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.